Pelvic inflammatory disease isolates of Neisseria gonorrhoeae are distinguished by C1q-dependent virulence for newborn rats and by the sac-4 region

The virulence mechanism of Neisseria gonorrhoeae in pelvic inflammatory disease (PID) is not well understood, and an objective diagnostic method to identify patients with PID is lacking. We investigated the hypothesis that development of PID was associated with a C1q-dependent virulence property of gonococcal strains. Recent development of a C1q-dependent experimental model of gonococcal infection (S. Nowicki, M. Martens, and B. Nowicki, Infect. Immun. 63:4790-4794, 1995) created an opportunity to evaluate this hypothesis in vivo. Therefore, the virulence of 32 clinical isolates (18 PID isolates and 14 local infection [LI] isolates) was evaluated in experimental rat pups. A serum bactericidal assay was used to characterize a gonococcal serum-resistant (ser(r)) phenotype. PCR primers designed to amplify a suitable-size gonococcal sac-4 DNA fragment (unique for serum-resistant donor JC1) were used to evaluate the association of serum-resistant genotype sac-4 with two phenotypes: C1q-dependent virulence expressed in vivo and resistance to bactericidal activity of human serum expressed in vitro. Strains were also characterized by auxotyping and serotyping. Of 32 gonococcal strains, 15 (46.7%) caused C1q-dependent bacteremia in rat pups and were sac-4 positive and ser(r). However, of the 15 isolates, 13 (87%) represented strains associated with human PID and 2 (13%) were associated with LI. None of the strains that were completely serum-sensitive (ser(s)) and sac-4 negative produced C1q-dependent bacteremia in rat pups, suggesting that both ser(r) and sac-4 were required for infection. The serum-resistant recombinant recipient of sac-4 produced C1q-dependent bacteremia in the rat model similarly to the serum-resistant donor of sac-4; the serum-sensitive parent strain did not produce bacteremia. These data suggest that sac-4-mediated serum resistance conferred C1q-dependent virulence and is a unique characteristic associated with PID. These newly identified features may contribute to the understanding of the pathogenic mechanism of PID-associated strains and open perspectives for establishing novel diagnostic methods.

[1]  B. Nowicki,et al.  Gonococcal infection in a nonhuman host is determined by human complement C1q , 1995, Infection and immunity.

[2]  Dhruv Kumar,et al.  Host Factors in the Attachment of Gonococcal Cells to Pelvic Tissue , 1994, Annals of the New York Academy of Sciences.

[3]  M. Goldacre,et al.  Morbidity following pelvic inflammatory disease , 1993, British journal of obstetrics and gynaecology.

[4]  F. Vivanco,et al.  C1q binding and activation of the complement classical pathway by Klebsiella pneumoniae outer membrane proteins , 1993, Infection and immunity.

[5]  P. Wölner‐Hanssen,et al.  Pathogenesis of pelvic inflammatory disease. , 1993, Genitourinary medicine.

[6]  S. Nowicki.  Possible Mechanisms of Serum Resistance of Neisseria gonorrhoeae from Disseminating Infections , 1991 .

[7]  P. Rice,et al.  Pathogenesis of pelvic inflammatory disease. What are the questions? , 1991, JAMA.

[8]  T. Trull.  Pelvic Inflammatory Disease: Research Directions in the 1990s: , 1991 .

[9]  J. Griffiss,et al.  In vitro and in vivo modification of Neisseria gonorrhoeae lipooligosaccharide epitope structure by sialylation , 1990, The Journal of experimental medicine.

[10]  S. E. West,et al.  Genetic loci and linkage associations in Neisseria gonorrhoeae and Neisseria meningitidis , 1989, Clinical Microbiology Reviews.

[11]  P. Rice.  Molecular basis for serum resistance in Neisseria gonorrhoeae , 1989, Clinical Microbiology Reviews.

[12]  J. Cole,et al.  Cytidine 5'-monophospho-N-acetyl neuraminic acid and a low molecular weight factor from human blood cells induce lipopolysaccharide alteration in gonococci when conferring resistance to killing by human serum. , 1988, Microbial pathogenesis.

[13]  R. P. Williams,et al.  A recombinant molecule from a disseminating strain of Neisseria gonorrhoeae that confers serum bactericidal resistance , 1987, Infection and immunity.

[14]  J. Schacter,et al.  The occurrence of chlamydial and gonococcal salpingitis during the menstrual cycle. , 1986, JAMA.

[15]  A. Washington,et al.  Hospitalizations for pelvic inflammatory disease. Epidemiology and trends in the United States, 1975 to 1981. , 1984, JAMA.

[16]  J. Cannon,et al.  Confirmation of association of protein I serotype of Neisseria gonorrhoeae with ability to cause disseminated infection , 1983, Infection and immunity.

[17]  E. Podack,et al.  Activation of complement by serum-resistant Neisseria gonorrhoeae. Assembly of the membrane attack complex without subsequent cell death , 1982, The Journal of experimental medicine.

[18]  J. Cannon,et al.  Genetics of Serum Resistance in Neisseria gonorrhoeae: The sac-1 Genetic Locus , 1981, Infection and immunity.

[19]  A. Masi,et al.  Disseminated gonococcal infection (DGI) and gonococcal arthritis (GCA): I. Bacteriology, epidemiology, host factors, pathogen factors, and pathology. , 1981, Seminars in arthritis and rheumatism.

[20]  D. Kasper,et al.  Natural serum bactericidal activity against Neisseria gonorrhoeae isolates from disseminated, locally invasive, and uncomplicated disease. , 1980, Journal of immunology.

[21]  P. Wølner-Hanssen,et al.  Pathogenesis of pelvic inflammatory disease. , 1979, British medical journal.

[22]  D. Katzenstein,et al.  Role of blocking antibody in disseminated gonococcal infection. , 1978, Journal of immunology.

[23]  S. Falkow,et al.  Characterization of an Escherichia coli plasmid encoding for synthesis of heat-labile toxin: molecular cloning of the toxin determinant , 1978, Infection and immunity.

[24]  F. Sanger,et al.  DNA sequencing with chain-terminating inhibitors. , 1977, Proceedings of the National Academy of Sciences of the United States of America.

[25]  K. Holmes,et al.  Gonococci causing disseminated gonococcal infection are resistant to the bactericidal action of normal human sera. , 1976, The Journal of clinical investigation.